Subject Index

A	Climbing behavlor 1	н
Abstinence syndrome 35	Clonidine 73	Haloperidol 7, 225, 237, 259
Activity 81, 231	Clorgyline 81	Head-poke activity 125
General — 293	Clortermine 251	Hippocampus 131
Locomotor — 301	CNS 181	Human subjects 11
Flexor reflex — 301	- stimulants 47	6-Hydroxydopamine 55, 73, 145
Acute Dystonia 237	Cocaine 47, 139	Hyperactive/aggressive children 29
Adrenaline 187	Codeine 153	Hypothermia 199
Aggression 215	Conditional suppression 139	
Alcohol 61	Continuous performance test (CPT) 29	1
Amitriptyline 29	Cortex 350	ID-1229 153
Amotivation syndrome 11	Cross dependence 153	Illumination 231
Amphepramone 165	Curiosity 275	Imipramine 21, 205
d-Amphetamine 139, 231, 251, 259, 309	Cyproheptadine 65	Intracerebral drug injections 293
Amphetamine 65, 95, 171, 215, 245		Intragastric 103
Angiotensin 149	D	Intravenous 103
Animal model 237		Intraventricular administration 89, 95
Animal model of psychosis 215	Deprenyl 81	— infusion 145
Anorectics 251	Depression 205	THI GOLDH THO
Antianxiety 113	Desynchronized sleep 171	K
Antipsychotics 1	Dextro-amphetamine 171	
Antipyrine 21	Diazepam 177, 193, 281	Kinetics 21
Anxiety 159	Diethylpropion 251	Kinins 181
Apomorphine 1, 47, 73, 225	Diurnal-rhythm 85	
Arousal 85	Dopamine 225	L
Avoidance 53, 211	— receptors 1	Lateral hypothalamus 61
	and Serotonin turnover 113	Learning 293
В	Dopamine-β-hydroxylease 259	Leucine incorporation 193
Baboons 251	Drug discrimination 119	Levo-amphetamine 171
Barbiturate-anaesthesia 85	— ingestion 350	Limbic system 131
Basal ganglia 350	— interaction 245	Lithium 81
Behavioral activity 145	 self-administration 251 	Locomotion 165
Behavioral disruption 125		Locomotor activity 301
Behavior 47, 73, 89, 165, 295	E	Locus ceruleus 193
operant 293	EEG 47, 131, 165	
sexual — 269	Electrical brain stimulation 61	M
social — 215	Electrodermal response 149	Marihuana 11
specific — 231	Epinephrine 149	Medial forebrain bundle 61
Benzodiazepines 41	Ethanol 61, 131	Mecloqualone 41
Biogenic amines 95, 181	model of physical dependence on —	Mental retardation 293
Blood ethanol concentration 107	107	Meprobamate 41
Brain gamma-aminobutyric acid 53	physical dependence on — 107	Metabolism 113
Brain norepinephrine 113	sustained intoxication with — 107	Metabolites of amines 181
Brain specific proteins 350	— withdrawal 125	Methadone 119
γ-Butyrolactone 225	— withdrawal syndrome 107	Methamphetamine 47, 245
	Excitatory amino acids 293	Methoxamine 145
C	Explorations 275	Methylenedioxyamphetamine (MDA) 251
Caffeine 47	-	Methylphenidate 29
Cannabis 199, 285	F	Mice 41
Cardiac conditioned response 159	Female cat 269	α-MT 95
Catalepsy 95	Fenfluramine 251	Model of physical dependence on
Catecholamines 199	Fixed-interval schedule 293	ethanol 107
Central nervous system 301	Flexor reflex activity 301	Monkeys 231
Chlordiazepoxide 113		Monoamines 301
Chlorphentermine 251	G	Morphine 119, 153, 309
Chlorpromazine 205, 281	General activity 293	Motor incoordination 281
Cigarette smoking 35	Canadantian 120	Multiple FI FR 65
	Generalization 139	Multiple FI FN 05

N

Naloxone 119, 211
Naltrexone 119
Narcosis 95
Narcotic antagonists 119
Narcotics 119
Neo-natal development 285
Nerve cell counts 350
Neuroleptic treatment 350
Noradrenaline 55
Norepinephrine 145
Nortriptyline 21

0

Open field 81 Operant behavior 53, 55, 293 Oxprenolol 177

F

PCPA 95
Pentazocine 153, 211
Perphenazine 350
Phenobarbital 41, 281
Phentermazine 251
Phentermine 251
Phentolamine 149
Phenylethylamines 251
Physical activity 11
Physical dependence 153
— on ethanol 107
Pigeons 211
Pimozide 225
Piperdine 301

Piribedil 225
Platelet MAO 187
Pre-natal administration 285
2-Propyl 2-pentenoic acid 53
Psychic and somatic anxiety symptoms
177
Psychoactive agents 275
Psychological tests 205
Psychopharmacology 205
Psychosis, animal model of — 215
Prostaglandins A₁, E₁, E₂, F₁, F₂, 89, 95
Pyrroxan 113

R

Rabbits 47, 131
Rats 41, 65, 73, 85, 89, 95, 103, 281
Rearing activity 125
Reinforcement 61
Reserpine 269
Rhesus monkey 159
Route of administration 103
Runway activity 125
— test 281

S

Saccharine 309
Schizophrenia 215
Seizures 165
Selective MAO inhibitors 81
Self-administration 103
— -stimulation 61
Sex-differences 85
Single-dose 21

Sleep 11, 113, 171 p-Sleep 171 Social-isolation 85 Stereotyped movements 165 Stress 187, 193 Supersensitivity 145 Sustained intoxication with ethanol 107 Synergism 65

T

Tardive dyskinesia 237
Δ°-Tetrahydrocannabinol 47, 159, 245
THC antagonists 47
Time judgment 7
Tolerance 285
— to ethanol 107
Tourette's syndrome 7
Tranylcypromine stereoisomers 81
Turnover 95
Tyrosine hydroxylase 55

Unit dose 103 ³H-Uridine uptake 350

٧

U

Variable-interval schedule 139 Vigilance performance 29

W

Waking 171 Water intake 41 Withdrawal syndrome 35

All you may ever need to know about the

SCIENCE CITATION INDEX[®]

but never found time to ask. If you've heard about the Science Citation Index, wondered how it works or compares with traditional subject indexes, here's your chance to get the full story.

A new, comprehensive booklet discusses every facet of this unique indexing system. And it's available to you without cost or obligation.

Just off press, this booklet is full of facts, figures, theory and how-to-use-it information. For example, you'll find discussions of:

 How the SCI* employs citation and Permuterm* subject indexing to avoid use of ambiguous terminology.

> How the SCI covers over 90% of the significant scientific and technical journal literature.

> > What is citation indexing?

 How the SCI's sophisticated, computer-based information processing reduces the time lag between original publication and indexing to a bare minimum.

 How to perform four basic types of literature searches—with sample indexing entries shown in detail.

So if you want to know all about the SCI, now's the time to ask. Send for your free booklet or ask for any reasonable number you may need for your organization.

Please send me ______
copies of your new booklet on the Science Citation Index® without cost or obligation.

Name

Organization

Address


City State ZIP

Country Telephone

Institute for Scientific Information®
325 Chestnut St., Phila., Pa. 19106, U.S.A., Tel: (215) 923-3300, Cable: SCINFO, Telex: 84-5305

SP 440





Gerocil verbessert Hämodynamik und Metabolismus im Gehirn

Indikationen: Zerebro-vaskulare Insuffizienz gen kommen, welche die Verkehrstuchtigkeit mit folgender Symptomatik. Kopfschmerzen, Konzentrationsmangel, Merkfahigkeitsstörungen, Verstimmungen, postapoplektische Zustande, postkommotionale Zustande, hirn-

Gerocii' ist nicht zur Behandlung des frischen Herzinfarktes geeignet. Bei besonders prädisponierten Patienten kann es im Einzelfall

Handelsformen und Preise: AVP incl. USt (Stand: 11.76). Originalpackungen ponierten Patienten kann es im Einzelfall

50 Kapseln = DM 19.20; 100 Kapseln = initial zu passageren Sedierungserscheinun-

herabsetzen Sie sind jedoch vorübergehend und können bei langsamer Steigerung auf die Optimaldosis vermieden werden

gen, Verstimmungen, postapoplektische Zustande, postkommotionale Zustande, hirntraumatische Folgezustande, vestibulare
Störungen wie Meniere-Syndrom und Vertigo
Kontraindikationen: Nicht bekannt.
Hinweise: Aus grundsatzlichen Erwägungen
ist Gerocii wie alle Arzneimittel während der
Schwangerschaft mit Vorsicht anzuwenden
Cerocii Laglich Zusammensetzung:
1 Kapsel enthält: 50 mg Cinnarizin, 5 mg
Vitamin-B₁-nitrat, 6 mg Vitamin B₂, 2 mg Vitamin-B₆-hydrochlorid, 150 mg Vitamin C.

USt (Stand 11.76) Originalpackungen 50 Kapseln = DM 19.20, 100 Kapseln = DM 35,30; Klinikpackung 'Trade Mark

Э JANSSEN GmbH DÜSSELDORF · LEOPOLDSTRASSE 16 · 4000 DÜSSELDORF · TEL.: (0211) 359031

